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Pimavanserin is claimed as the first antipsychotic drug that shows selectivity for serotonin 5- 
HT 2 receptors (5-HT 2 Rs) and lacks of affinity for dopamine D 2 receptors (D 2 Rs). Cell-based func- 
tional assays suggest that pimavanserin and antipsychotics with D 2 R/5-HT 2 R affinity could act 
as inverse agonists of 5-HT 2A Rs. However, there is not evidence of such pharmacological profile 
in native brain tissue. 5-HT 2A Rs are able to engage both canonical G αq/11 - and non-canonical 
G αi1 -proteins. In the present study, the response to pimavanserin of the 5-HT 2A R coupling to 
G αq/11 - and G αi1 -proteins was measured in membranes of postmortem human prefrontal cortex 
by antibody-capture [ 35 S]GTP γ S binding scintillation proximity assays. Pimavanserin promoted 
a concentration-dependant inhibition of the 5-HT 2A R coupling to G αi1 -proteins whereas the re- 
sponse of G αq/11 -proteins was unaltered, suggesting inverse agonism and neutral antagonism 
properties, respectively. The inhibition was abolished in the presence of the selective 5-HT 2A R 
antagonist MDL-11,939 and was absent in brain cortex of 5-HT 2A R knock-out mice when com- 
pared to respective 5-HT 2A R wild-type animals. In conclusion, the results demonstrate the ex- 
istence of constitutive 5-HT 2A R activity in human brain for the signalling pathway mediated by 
G αi1 -proteins. Pimavanserin demonstrates 5-HT 2A R functional selectivity and exhibits inverse 
agonist profile towards G αi1 -proteins, which is considered the effector pathway promoting hal- 
lucinogenic responses. In contrast, pimavanserin behaves as neutral antagonist on the 5-HT 2A R 
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coupling to the canonical G αq/11 -protein pathway. The results strengthen the relevance of in- 
verse agonism as potential mechanism of antipsychotic activity. Moreover, the existence of 
functional selectivity of 5-HT 2A Rs for different G α-proteins could contribute to better design of 
5-HT 2A R-related antipsychotic drugs. 
© 2020 The Author(s). Published by Elsevier B.V. 
This is an open access article under the CC BY-NC-ND license. 



























































































The development of new antipsychotic drugs with improved
effectiveness, better impact on functional impairment, and
less side effects represents a challenge for the current
treatment of schizophrenia and related disorders. Tradition-
ally, antipsychotic efficacy is considered to be mediated
by antagonism of the dopamine D 2 receptor (D 2 R). Most of
second-generation or “atypical” antipsychotic drugs have in
common a higher affinity for the serotonin 5-HT 2A recep-
tor (5-HT 2A R) than D 2 Rs ( Meltzer, 1999 ). Nonetheless, the
lack of efficacy of monotherapy with selective 5-HT 2A R an-
tagonists (volinanserin or MDL-100,907) led to thought that
5-HT 2A R actions are incremental whereas affinity for D 2 Rs
represents the essential component of antipsychotic activ-
ity ( Miyamoto et al., 2005 ). Recently, a potent and selective
5-HT 2A R drug, pimavanserin (ACP-103), was developed as a
new alternative for the treatment of psychosis ( Meltzer and
Roth, 2013 ). Pimavanserin displays nanomolar potency as
5-HT 2A R inverse agonist, selectivity for 5-HT 2A Rs over 5-
HT 2C receptors (5-HT 2C Rs), and no significant activity at any
other G-protein coupled receptor (GPCR) ( Vanover et al.,
2006 ). Until now, pimavanserin has been studied as adjunc-
tive therapy for schizophrenia ( Meltzer et al., 2012 ) and
has gained FDA approval to reduce delusions and halluci-
nations in Parkinson’s disease ( Cummings et al., 2014 ). In
these patients, atypical antipsychotics administration could
worsen efficacy of standard anti-parkinsonian drugs due
to their antagonism on D 2 R family. Besides, a pilot study
demonstrated marked response to pimavanserin of refrac-
tory positive symptoms in clozapine-nonresponsive patients
( Nasrallah et al., 2019 ). Therefore, pimavanserin is claimed
as the first 5-HT 2A R drug that lacks of D 2 R affinity but shows
antipsychotic activity ( Hacksell et al., 2014 ). The evaluation
of pimavanserin pharmacological profile suggests that could
act as inverse agonist of 5-HT 2A Rs ( Vanover et al., 2006 ).
However, the limited information on its inverse agonism
properties have raised important concerns and prompted
to the search of better evidence in human brain before to
conclude that pimavanserin behaves as inverse agonist of
5-HT 2A Rs ( Nutt et al., 2017 ). 
Inverse agonism is considered the pharmacological prop-
erty of a drug to antagonize the action of agonists and simul-
taneously lower the basal constitutive activity of receptor
signalling. Different studies have hypothesized that clinical
activity of atypical antipsychotics is due to their inverse ag-
onist properties at 5-HT 2A Rs and 5-HT 2C Rs ( Sullivan et al.,
2015 ; Weiner et al., 2001 ). However, it is noteworthy to
remark that the negative intrinsic activity of these drugs
has been described in cell culture assays where increased
constitutive activity is usually present. In contrast, exper- 
iments with native tissue are scarce and the existence of
constitutive 5-HT 2A R activity in brain is still a matter of de-
bate ( Aloyo et al., 2009 ; De Deurwaerdère et al., 2020 ).
In this context, it is uncertain if the clinical effect of pima-
vanserin is due to its inverse agonism properties on 5-HT 2A Rs
( Nutt et al., 2017 ). 
GPCRs, and amongst them the 5-HT 2A R, can be acti-
vated by chemically distinct drugs to preferentially en-
gage different signalling pathways. This mechanism is
termed biased agonism or functional selectivity ( Berg and
Clarke, 2018 ). For instance, in brain, the 5-HT 2A R is able
to discriminate activation of G αq/11 -, G αi/o -proteins and
other signalling pathways in response to diverse agonists
( González-Maeso et al., 2007 ; Schmid and Bohn, 2010 ).
Thus, 5-HT 2A R agonist drugs with hallucinogenic proper-
ties such as lysergic acid diethylamide (LSD), psilocy-
bin, mescaline and ( ±)DOI promote activation of the
canonical G αq/11 -protein cascade as well as G αi/o -protein-
mediated signalling pathways. In contrast, chemically anal-
ogous 5-HT 2A R agonists lacking of hallucinogenic proper-
ties (lisuride, ergotamine) only stimulate G αq/11 -protein-
dependant pathways ( González-Maeso et al., 2007 ; López-
Giménez and González-Maeso, 2018 ). These findings sug-
gest that the fingerprint of pro-hallucinogenic and, per-
haps, anti-hallucinogenic properties of 5-HT 2A R drugs de-
pend on modulation of G αi/o -proteins and their down-
stream signalling pathways ( López-Giménez and González-
Maeso, 2018 ). Recently, supersensitivity of the 5-HT 2A R cou-
pling to G αi1 -proteins but not to G αq/11 -proteins in post-
mortem brain of subjects with schizophrenia has been
described ( Garcia-Bea et al., 2019 ). This result pro-
vides further support for the suggestion that selective 5-
HT 2A R antagonists/inverse agonists with functional selectiv-
ity on G αi1 -proteins might be useful tools as antipsychotic
drugs. 
In the present study, the pharmacological profile of pi-
mavanserin was investigated to elucidate whether this an-
tipsychotic drug behaves as antagonist or inverse agonist of
5-HT 2A R in native postmortem human brain tissue. The mod-
ulation of 5-HT 2A R coupling to G αq/11 - and G αi1 -proteins in
response to pimavanserin was measured to clarify the exis-
tence of putative functional selectivity of this drug towards
pro-hallucinogenic pathways. 
2. Experimental procedures 
2.1. Brain cortex membranes preparation 
Human brain samples were obtained at autopsy in the Basque In-
stitute of Legal Medicine, Bilbao, Spain, in compliance with poli-





















































































































[  ies of research and ethical boards for postmortem brain studies at
he moment of sample obtaining. All the subjects were determined
o be free of neurological and psychiatric disorders based on med-
cal records and postmortem tissue examinations. Positive blood 
oxicology for drugs or ethanol was considered exclusion criteria. 
amples from the dorsolateral prefrontal cortex were dissected at 
utopsy following established protocols ( Muguruza et al., 2013 ) and
mmediately stored at −70 °C until assay. Samples of six different
ubjects (5 males and 1 female) with ages between 29–77 years
ere included. The postmortem delay between death and storage
f the samples ranged from 7 to 29 h. 
The 5-HT 2A R knock-out (5-HT 2A R (-/-) ) and wild-type (5-
T 2A R ( + / + ) ) mice were generously donated by Prof. R. Maldon-
do (Barcelona, Spain). Animals were originally generated on a 
29S6/SvEv background and subsequently backcrossed onto the 
nbred C57BL/6J line following standard procedures ( González- 
aeso et al., 2007 ; Viñals et al., 2015 ). After donation, supple-
entary backcrosses were performed. Animals were genotyped by 
olymerase chain reaction (PCR). Absence of 5-HT 2A R expression 
n 5-HT 2A R (-/-) mice was confirmed by the lack of [ 3 H]ketanserin
inding ( Muguruza et al., 2013 ) and G q/11 -/G i1 -protein activation
y ( ±)DOI ( García-Bea et al., 2019 ). Adult mice were sacrificed by
ervical dislocation, brains removed, cortex dissected and samples 
tored at −70 °C until assay. Animal care and experimental proto-
ols were done in agreement with European Union regulations and
pproved by the UPV/EHU institutional Ethics Committee for animal 
elfare (CEEA). 
Membrane enriched fractions (P 2 ) from human and mice samples
ere prepared as previously described ( Diez-Alarcia et al., 2016 ). 
.2. Antibody-capture [ 35 S]GTP γS binding scintillation 
roximity assay (SPA) 
ssays were performed as described ( Diez-Alarcia et al., 2016 )
ollowing experimental conditions for determination of in- 
erse agonism properties of different drugs in postmortem 
uman brain ( Diez-Alarcia et al., 2019 ; Erdozain et al., 2012 ).
oncentration-effect response (10 −10 –10 −4 M) curves for spe- 
ific coupling/uncoupling of G αq/11 - and G αi1 -proteins by 1- 
4-fluorobenzyl) −3-(4-isobutoxybenzyl) −1-(1-methylpiperidin- 
-yl)urea (pimavanserin; ACP-103) and α-phenyl-1-(2- 
henylethyl) −4-piperidinemethanol (MDL-11,939) were performed. 
DL-11,939 was chosen as selective 5-HT 2A R vs 5-HT 2C R antag-
nist ( Knight et al., 2004 ; Pehek et al., 2006 ). Pergolide and
 ±) −2,5-dimethoxy-4-iodoamphetamine (DOI) activity on G αq/11 - 
nd G αi1 -proteins was used to validate the experimental condi-
ions for detecting the functional selectivity on 5-HT 2A Rs. These
ompounds were chosen as representative non-hallucinogenic and 
allucinogenic 5-HT 2A R agonists, respectively, and were tested at 
aximal concentration (10 μM) with and without the antagonist
DL-11,939 (1 μM). Additionally, specific coupling/uncoupling 
esponses of inhibitory G αi2 -, G αi3 - and G αo -proteins at maximal
imavanserin concentration (10 μM) were performed. On the other 
and, in order to confirm the 5-HT 2A R involvement in the effects of
imavanserin, one-point concentration experiments (10 μM) in the 
bsence and presence of the antagonist MDL-11,939 (1 μM) were
arried out both in human and in 5-HT 2A R ( + / + ) and 5-HT 2A R (-/-) 
ice brain samples. Briefly, [ 35 S]GTP γ S binding was performed in
uffer containing 0.4 nM [ 35 S]GTP γ S, 11 μg of protein/well and
0–100 μM GDP. After [ 35 S]GTP γ S binding, immunoprecipitation 
ith specific antibodies for each G α-protein subunit and protein
 polyvinyltoluene SPA beads was carried out. Plates were then
entrifuged and bound radioactivity detected on a MicroBeta 
riLux scintillation counter. Non-specific binding was defined as the 
emaining [ 35 S]GTP γ S binding in the presence of 100 μM unlabelled
TP γ S. .3. Data analysis and statistical procedures 
ata were analysed with GraphPad Prism TM 5.01. Specific 
 
35 S]GTP γ S binding values obtained from SPA assays were trans-
ormed to percentage of basal [ 35 S]GTP γ S binding (binding values
n the absence of any exogenous drug) obtained for each G α-protein
nd considered as 100%. Concentration that promotes half-maximal 
ffect (IC 50 ) and maximal inhibitory effect (I max ) values were cal-
ulated, when possible, by nonlinear curve fitting of concentration-
esponse experiments. Results from single-point maximal concen- 
ration experiments were analysed by one-, and two-sample Stu-
ent’s t -test vs basal values (expressed as 0%) or between exper-
mental groups, respectively. Data are described as mean ±S .E.M.
alues. Graphical representations of results are displayed as 
oncentration-response curves or as box and whiskers plots. 
.4. Antibodies, drugs and reagents 
onoclonal antibodies against G αq/11 - (sc-515689), G αi1 - (sc-56536),
 αi2 - (sc-13534), G αi3 - (sc-365422) and G αo - (sc-393874) proteins
ere obtained from Santa Cruz Biotechnologies (USA). Specificity 
emonstration of G αq/11 - and G αi1 -protein antibodies vs the differ-
nt recombinant and brain tissue G-proteins is shown in Supplemen-
ary Figure S1. Pimavanserin and pergolide were supplied by Med-
hem Tronica Ab (Sweden) and MDL-11,939 (glemanserin) by Tocris
ioscience (UK). ( ±)DOI was obtained from Sigma-Aldrich (USA).
 
35 S]GTP γ S was purchased from Perkin Elmer Life Sciences (Ger-
any). Other reagents for SPA were obtained from Sigma-Aldrich
nd Perkin Elmer Life Sciences. 
. Results 
.1. Effects of pimavanserin and MDL-11,939 on 
 αq/11 -, and G αi/o -proteins in human brain 
he [ 35 S]GTP γ S binding to G αq/11 -proteins in response
o increasing concentrations of pimavanserin and MDL- 
1,939 was unaltered ( Fig. 1 A), suggesting that these
rugs act as neutral antagonists on the canonical path-
ay of 5-HT 2A Rs. In contrast, pimavanserin displayed a
oncentration-dependant inhibition of the [ 35 S]GTP γ S bind- 
ng to G αi1 -proteins with IC 50 = 3.5 nM (-logIC 50 = 8.46 ±0.2)
nd I max = 25 ±2% ( Fig. 1 B), which denotes an inverse agonist
rofile on this signalling pathway in human prefrontal cor-
ex. MDL-11,939 showed a null effect on [ 35 S]GTP γ S bind-
ng to G αi1 -proteins, indicating a pharmacological profile of
eutral antagonist ( Fig. 1 B). 
In a new set of experiments, responses to pimavanserin
10 μM) were tested on other G αi/o -proteins (G αi2 , G αi3 and
 αo ). At this maximal concentration, pimavanserin did not
isplay significant activity on [ 35 S]GTP γ S binding to any of
hese inhibitory G α-proteins, which could reflect a pure an-
agonist profile or, alternatively, the absence of constitu- 
ive activity of these G αi/o -proteins in human brain cortex
 Fig. 2 ). 
.2. Involvement of 5-HT 2A Rs in the effects of 
imavanserin in human brain 
n order to demonstrate that pimavanserin-induced 
 
35 S]GTP γ S binding inhibition to G αi1 -proteins represents in-
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Fig. 1 Concentration-response curves of the specific 
[ 35 S]GTP γ S binding to G αq/11 -proteins ( A ) and G αi1 -proteins ( B ) 
obtained for pimavanserin and MDL-11,939 in prefrontal human 
brain cortex membranes. The 100% line denotes the specific 
[ 35 S]GTP γ S basal binding to respective G α-proteins. Points and 
bars represent mean ±S .E.M. response values for each drug 
concentration. C. Modulation of specific [ 35 S]GTP γ S binding 
to G αq/11 - and G αi1 -proteins by 10 μM pimavanserin alone and 
co-incubated with the 5-HT 2A R antagonist MDL-11,939 (1 μM) 
in prefrontal human brain cortex. Basal values of specific 
[ 35 S]GTP γ S binding to G αq/11 - and G αi1 -proteins are expressed 
as 0% and stimulatory/inhibitory effects on the respective basal 
are shown . Each box spans the 25–75 interquartile range and 
whiskers extend to the 5% −95% observations. The line inside 
the box indicates median value. Independent experiments 
were carried out by triplicate in samples of six subjects. 
∗∗∗p < 0.001 vs basal values (one-sample t -test); ## p < 0.01 






Fig. 2 Modulation of specific [ 35 S]GTP γ S binding to G αq/11 - 
, G αi1 -, G αi2 -, G αi3 - and G αo -proteins by 10 μM pimavanserin 
in prefrontal human brain cortex. Basal values of specific 
[ 35 S]GTP γ S binding to the different G-proteins are expressed 
as 0% and stimulatory/inhibitory effects on the respective 
basal are shown . Each box spans the 25–75 interquartile range 
and whiskers extend to the 5% −95% observations. The line 
inside the box indicates median value. Independent experi- 
ments were carried out by triplicate in samples of six subjects. 

































verse agonism mediated by 5-HT 2A Rs, MDL-11,939 (1 μM)
was employed to antagonize the effect. The inhibition in-
duced by pimavanserin at 10 μM (20 ±2%) on [ 35 S]GTP γ S
binding to G αi1 -proteins was abolished when co-incubated
with MDL-11,939 (1 μM) (2 ± 2%) ( p < 0.01 between groups),supporting the involvement of 5-HT 2A Rs ( Fig. 1 C). As ex-
pected, pimavanserin (10 μM) neither alone nor in the pres-
ence of MDL-11,939 (1 μM) modified [ 35 S]GTP γ S basal bind-
ing to G αq/11 -proteins ( Fig. 1 C). 
Given the absence of pimavanserin and MDL-11,939 ef-
fects on G αq/11 -protein activation, it was necessary to
demonstrate a measurable response of this signalling path-
way to 5-HT 2A R activation by agonists. Pergolide was cho-
sen as a non-hallucinogenic drug with high (although non-
selective) affinity for 5-HT 2A Rs ( Odagaki et al., 2019 ). On
the other hand, ( ±)DOI was selected as representative hal-
lucinogenic LSD-like drug ( López-Giménez and González-
Maeso, 2018 ) with high affinity for 5-HT 2A Rs and 5-HT 2C Rs
( Knight et al., 2004 ). Consistent with the hypothesis, per-
golide (10 μM) was able to stimulate [ 35 S]GTP γ S basal bind-
ing to G αq/11 - (31 ±3%; p < 0.001 vs basal) but not to G αi1 -
proteins (1 ± 2%). In contrast, ( ±)DOI at 10 μM increased
the [ 35 S]GTP γ S binding to both G αq/11 - (17 ±2%; p < 0.001 vs
basal) and G αi1 -proteins (15 ±2%; p < 0.001 vs basal) (Sup-
plementary Figure S2). The selective 5-HT 2A R antago-
nist MDL-11,939 (1 μM) partially abolished the pergolide-
mediated G αq/11 -protein activation (13 ±2%) ( p < 0.001 be-
tween groups). In the case of ( ±)DOI, the presence of
MDL-11,939 (1 μM) blocked the stimulation of both G αq/11 -
( −1 ± 1%; p < 0.0001 between groups) and G αi1 -proteins
(0 ± 2%; p < 0.001 between groups) (Supplementary Figure
S2). 
3.3. Effects of pimavanserin on G αq/11 -, and 
G αi1 -proteins in 5-HT 2A R (-/-) and 5-HT 2A R ( + / + ) mice 
To further ensure that the pharmacological profile of pima-
vanserin obtained in human brain corresponds to activity on
5-HT 2A Rs, equivalent assays were performed in brain cor-
tex of 5-HT 2A R ( + / + ) and 5-HT 2A R (-/-) mice. No effects of pi-
mavanserin (10 μM) were observed for [ 35 S]GTP γ S binding
to G αq/11 -proteins in any of the genotypes ( Fig. 3 ). How-
ever, a significant inhibition (13 ±2%; p < 0.01 vs basal) of
Inverse agonism of pimavanserin on 5-HT 2A receptors 87 
Fig. 3 Modulation of specific [ 35 S]GTP γ S binding to G αq/11 - and 
G αi1 -proteins by 10 μM pimavanserin in brain cortex membranes 
of 5-HT 2A R ( + / + ) (white boxes) and 5-HT 2A R (-/-) (dark boxes) 
mice. Basal values of specific [ 35 S]GTP γ S binding to G αq/11 - and 
G αi1 -proteins are expressed as 0% and stimulatory/inhibitory ef- 
fects on the respective basal are shown . Absolute values of the 
specific [ 35 S]GTP γ S basal binding to G αq/11 -, and G αi1 -proteins 
were not different between 5-HT 2A R ( + / + ) and 5-HT 2A R (-/-) mice 
(data not shown). Each box spans the 25–75 interquartile range 
and whiskers extend to the 5% −95% observations. The line in- 
side the box indicates median value. Independent experiments 
were carried out by triplicate in samples of five to seven an- 
imals. ∗∗p < 0.01 vs basal values (one-sample t -test); ## p < 0.01 





























































































he [ 35 S]GTP γ S binding to G αi1 -proteins was observed in 5-
T 2A R ( + / + ) mice. In contrast, the pimavanserin-induced in- 
ibition of the G αi1 -protein activity was not found in 5-
T 2A R (-/-) mice (2 ± 2%) ( p < 0.01 between genotypes), con-
rming the inverse agonist properties on this non-canonical 
ignalling pathway of 5-HT 2A Rs. ( Fig. 3 ). 
. Discussion 
he present study provides evidence that pimavanserin dis- 
lays inverse agonist properties on 5-HT 2A Rs in postmortem 
uman frontal cortex. This pharmacological profile of pima- 
anserin is highly selective for the 5-HT 2A R coupling to G αi1 -
roteins whereas the drug operates as neutral antagonist on 
he signalling pathway mediated by G αq/11 -proteins. Over- 
ll, the finding sheds light on consistent objections raised 
bout the true pharmacological profile of pimavanserin in 
ative tissue and, specifically, in human brain ( Nutt et al.,
017 ). Moreover, since the hallucinogenic-like effects of 5- 
T 2A R agonists such as LSD, psilocybin, mescaline, ( ±)DOI
nd analogues seem to be mediated through the G αi1 -
rotein ( González-Maeso et al., 2007 ; López-Giménez and 
onzález-Maeso, 2018 ), the ability of pimavanserin to pref- 
rentially uncouple 5-HT 2A Rs from this G α-protein should be 
egarded as critical to better understand the mechanisms 
f antipsychotic activity. Accordingly with this hypothesis, 
he present results in postmortem human brain of differen- 
ial G α-protein recruitment by the agonists pergolide and 
 ±)DOI confirm previous findings in animals and cell cul-
ures that proposed activation of the G αi1 -protein signalling 
athway as a fingerprint of hallucinogenic-like properties 
or 5-HT 2A R agonist drugs ( López-Gimenez and González- 
aeso, 2018 ). 
Demonstration that a particular drug shows inverse ago- 
ist properties requires the existence of constitutive basal ctivity that should be reduced by the candidate compound.
he decrease of constitutive activity must be sensitive to
lockade with an antagonist and be absent in knock-out an-
mals for the involved receptor ( Aloyo et al., 2009 ). Up to
ow, the existence of constitutive activity of the 5-HT 2A R
epresented an unresolved issue ( De Deurwaerdère et al.,
020 ). Attempts to demonstrate in vitro constitutive basal 
ctivity of this receptor have required either receptor muta-
enesis ( Egan et al., 1998 ) or overexpression ( Weiner et al.,
001 ) in transfected cells. However, these approaches do
ot reproduce accurately the molecular signalling of 5- 
T 2A Rs in native tissue, which is essential to identify the
ntipsychotic mechanisms of action. In the current in vitro
tudy, the existence of constitutive 5-HT 2A R basal activity
oward the G αi1 -protein subtype is demonstrated in human
nd mice brain cortex. The inverse agonist activity of pima-
anserin on this signalling pathway is supressed by a candi-
ate antagonist drug, MDL-11,939, whose neutral antagonist 
roperties are also proved. Finally, the inverse agonism pro-
le of pimavanserin is absent in 5-HT 2A R (-/-) mice. A further
ondition to establish definitively the existence of constitu- 
ive receptor activity under in vitro conditions is the demon-
tration that signalling deactivation occurs in the absence 
f the endogenous neurotransmitter ( Aloyo et al., 2009 ).
n the present condition, the processing of brain tissue ho-
ogenates to obtain membrane-enriched fractions is based 
n strong centrifugations and washouts, which precludes 
he presence of significant trace amounts of serotonin in the
edium. Even more, if that possibility were true, inverse
gonism of pimavanserin would be expected to appear on
ll the G α-proteins, lacking of subtype selectivity, and MDL-
1,939 would show similar profile to pimavanserin. Previ- 
usly, indirect evidence of constitutive 5-HT 2A R activity in
ostmortem human frontal cortex was suggested by demon- 
trating that the non-hydrolyzable GTP analogue Gpp(NH)p, 
hich uncouples receptor from G-proteins, enhances the 5- 
T 2A R population identified by the inverse agonist altanserin
 Muguruza et al., 2013 ). However, identification of the G αi1 -
rotein as the specific effector pathway responsible for the
onstitutive activity of 5-HT 2A Rs in brain has not been con-
lusively determined until now. 
The possibility that antipsychotic drugs with significant 
ffinity for D 2 R and 5-HT 2A Rs such as clozapine, risperidone
nd olanzapine could mediate some of their clinical effects
hrough inverse agonism on 5-HT 2A Rs and other GPCRs has
een speculated ( Sullivan et al., 2015 ). The argument is
upported on transient expression screening studies per- 
ormed in cells and the assessment of phospholipase C and
hospholipase A 2 signalling responses in these cell cultures 
 Egan et al., 1998 ; Weiner et al., 2001 ). However, caution
hould be taken in mind since no functional study has been
esigned yet in native tissue conditions to test the putative
nverse agonist profile of antipsychotics and, particularly, 
heir activity on the non-canonical G αi1 -protein pathway. 
Certainly, the present study does not directly demon- 
trate that recruitment of G αi1 -protein signalling pathway 
epresents the mechanism of antipsychotic activity of pi- 
avanserin and, perhaps, other relevant drugs. However, 
he coupling preference of 5-HT 2A Rs to G αi1 -protein in-
tead of canonical G αq/11 -proteins to induce hallucinogenic- 
ike symptoms in animals ( González-Maeso et al., 2007 ;
ópez-Giménez and González-Maeso, 2018 ) and the over- 






















































































active 5-HT 2A R coupling to G αi1 -, but not G αq/11 -proteins,
in schizophrenia ( García-Bea et al., 2019 ) should be rele-
vant outputs to consider in the analysis of the therapeu-
tic role played by the 5-HT 2A R inverse agonism. Elucidation
of the structure of 5-HT 2A Rs in complex with antipsychotic
drugs and docking studies could help to the rational de-
sign of compounds displaying functional selectivity for the
G αi1 -protein pathway ( Kimura et al., 2019 ). On the other
hand, a crucial point is to ascertain whether an enhanced
constitutive activity of 5-HT 2A R coupling to G αi1 -proteins is
present in brain of subjects with schizophrenia. This would
strengthen the relevancy of inverse agonism vs neutral an-
tagonism as mechanism to improve the efficacy and/or tol-
erability of 5-HT 2A R-related antipsychotic drugs. In this con-
text, it should be kept in mind, when considering clinical
evaluation of pimavanserin as adjunct treatment to antipsy-
chotics, that the singular efficacy elicited by pimavanserin
might be hidden by addition of another antipsychotic with
neutral antagonist profile on 5-HT 2A Rs signalling towards
G αi1 -proteins. 
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